CoChat

Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy

Open access
Morin, Charles M. · 2020 · Expert Review of Medical Devices

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Introduction: Prescription digital therapeutics (PDTs) represent a new class of software-based medical devices authorized by the Food and Drug Administration (FDA) to treat disease. Somryst™, the first PDT for treating chronic insomnia, delivers cognitive behavioral therapy for insomnia (CBT-I) via a mobile application. CBT-I is the guideline-recommended, first-line treatment for chronic insomnia, but availability of CBT-I therapists is limited. Somryst addresses this need by providing asynchronous access to CBT-I treatment. As a contactless therapeutic medium, Somryst is also an ideal option when face-to-face therapy is not available or recommended for safety reasons (e.g. because of possible exposure to the SARS-CoV-2 virus).Areas covered: This review summarizes the mechanisms of action and technical features of Somryst, and describes safety and effectiveness data from the randomized trials on which FDA clearance was based.Expert opinion: Somryst demonstrates robust clinical efficacy with a favorable benefit-to-risk profile for treating adults with chronic insomnia. FDA clearance was based on data from 2 clinical trials of the first-generation web-based CBT-I platform Sleep Healthy Using the Internet (SHUTi). Somryst, and PDTs in general, are promising devices to address the need for greater accessibility to effective therapies.

Overview

Integrity signals

Registry

Crossref · 10.1080/17434440.2020.1852929

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 59 references

Research works printed but not linked: 8

  1. American Academy of Sleep Medicine, 2014, International classification of sleep disorders
  2. Ancoli-Israel S, 1999, Sleep, 22, S347
  3. Shore JH, 2020, JAMA Psychiatry
  4. Morin CM, 1993, Treatment manuals for practitioners
  5. 10.1001/jamapsychiatry.2016.3249 · DOI · Paper page
  6. 10.1037/0022-006X.69.1.58 · doi:10.1037/0022-006x.69.1.58 · Paper page
  7. Center for Devices Radiological Health, 2017, De novo summary for reSET (DEN160018)
  8. Food and Drug Administration. Guidance for the content of premarket submissions for software contained in medical devices

Cited by

See all 66

Metadata

Authors
Morin, C. M.
Affiliations
Université Laval (CA)
Corresponding author
Morin, Charles M.
Venue
Expert Review of Medical Devices
Published
2020-12-01
Volume
17
Issue
12
Pages
1239-1248
ISSN
  • 1743-4440 (ISSN-L)
  • 1745-2422
OpenAlex
W3108593994
Cited by
66
References
59
Citations by year
2026: 7 · 2025: 10 · 2024: 17 · 2023: 16 · 2022: 10 · 2021: 6
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • Expert Review of Medical Devices (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
funded by Pear Therapeutics, Inc
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
  • Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
Keywords
prescription digital therapeutics, chronic insomnia, cognitive behavioral therapy for insomnia, mobile application, FDA clearance, treatment efficacy and safety, telemedicine, SARS-CoV-2 exposure
MeSH terms
COVID-19, SARS-CoV-2, Chronic Disease, Humans, Sleep Initiation and Maintenance Disorders, Cognitive Behavioral Therapy, Prescriptions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy. https://app.cochat.ai/papers/10.1080/17434440.2020.1852929
The paper
Morin, C. M. (2020). Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy. Expert Review of Medical Devices. https://doi.org/10.1080/17434440.2020.1852929

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.